icone plus
Contact Abonnez-vous aux actualités
Reason for request
Reassessment
Clinical Benefit
Insufficient
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding.
Clinical Added Value
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
xQz337hBRkKAjQVt
Listen
